AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2021
Aug 19, 2021
31100_dirs_2021-08-18_693d37e0-f149-4fb5-9ccf-84d9ebd83ac2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-08-16
Reporting Person: Wright-Mitchell Jane (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-16 | Common Stock | M | 2500 | $2.03 | Acquired | 5625 | Direct |
| 2021-08-16 | Common Stock | S | 2500 | $26.00 | Disposed | 3125 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-16 | Stock Option (right to buy) | $2.03 | M | 2500 | Disposed | 2029-03-20 | Common Stock (2500) | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 24